{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:20:39Z","timestamp":1783178439666,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.clinthera.2005.07.004","type":"journal-article","created":{"date-parts":[[2005,9,10]],"date-time":"2005-09-10T07:39:42Z","timestamp":1126337982000},"page":"1032-1042","source":"Crossref","is-referenced-by-count":17,"title":["Simulation of Antibiotic Pharmacodynamic Exposure for the Empiric Treatment of Nosocomial Bloodstream Infections: A Report from the OPTAMA Program"],"prefix":"10.1016","volume":"27","author":[{"given":"Dana","family":"Maglio,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kuti,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.07.004_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.271.20.1598","article-title":"Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality","volume":"271","author":"Pittet","year":"1994","journal-title":"JAMA."},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.07.004_bib2","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1086\/314078","article-title":"Nosocomial bloodstream infections: Organ isms,risk factors, and implications","volume":"31","author":"Karchmer","year":"2000","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.145.9.1621","article-title":"Pseudomonas bacteremia. Retrospective analysis of 410 episodes","volume":"145","author":"Bodey","year":"1985","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2005.07.004_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/clind\/24.4.584","article-title":"The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults","volume":"24","author":"Weinstein","year":"1997","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest."},{"key":"10.1016\/j.clinthera.2005.07.004_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis."},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.07.004_bib7","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1086\/314079","article-title":"Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients","volume":"31","author":"Kollef","year":"2000","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2004.05.003","article-title":"Occurrence and an timicrobial resistance pattern comparisons among blood-stream infection isolates from the SENTRY antimicrobial surveillance program (1997\u20132002)","volume":"50","author":"Biedenbach","year":"2004","journal-title":"Diag Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ajic.2003.09.002","article-title":"National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003","volume":"31","author":"NNIS","year":"2003","journal-title":"Am J Infect Control."},{"key":"10.1016\/j.clinthera.2005.07.004_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolones use","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.clinthera.2005.07.004_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0732-8893(03)00112-3","article-title":"Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America","volume":"47","author":"Rhomberg","year":"2003","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimi crobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib13","first-page":"203","article-title":"When \u2018S\u2019 doesn't mean success: The importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection","volume":"69","author":"Gillespie","year":"2005","journal-title":"Conn Med."},{"key":"10.1016\/j.clinthera.2005.07.004_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibiotic dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib18","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.48.7.2464-2470.2004","article-title":"Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002","volume":"48","author":"Kuti","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.diagmicrobio.2004.03.003","article-title":"Pharmacodynamic comparisons of antimicrobials against noso comial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa from the MYSTIC surveillance program: The OPTAMA Program, SouthAmerica 2002","volume":"49","author":"Kiffer","year":"2004","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/dkh511","article-title":"The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe","volume":"55","author":"Masterton","year":"2005","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.47.1.292-296.2003","article-title":"Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team","volume":"47","author":"Jones","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics-pharmacodynamics of cefepime and piperacillin\/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta lactamases: Report from the ARREST program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.40.1.105","article-title":"Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenemcilastatin","volume":"40","author":"Dreetz","year":"1996","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib24","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1128\/AAC.39.11.2503","article-title":"Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa","volume":"39","author":"Klepser","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib25","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1128\/AAC.34.12.2307","article-title":"Pharmacokinetics of ceftazidime in serum and suction blister fluidduring continuous and intermittent infusion in healthy volunteers","volume":"34","author":"Mouton","year":"1990","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/24.1.23","article-title":"Pharmacokinetics and tissue penetration of cefepime","volume":"24","author":"Nye","year":"1989","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib27","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/AAC.41.11.2511","article-title":"Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillintazobactam regimens","volume":"41","author":"Occhipinti","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2004.02.003","article-title":"Antimicrobial resistance ratesand clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: Report of year five (2003)","volume":"49","author":"Rhomberg","year":"2004","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib29","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2002"},{"key":"10.1016\/j.clinthera.2005.07.004_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkh232","article-title":"Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001\u20132002: The BSAC Bacteraemia Resistance Surveillance Programme","volume":"53","author":"Reynolds","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib32","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Use of pharmacokinetics-pharmacodynamics and Monte Carlo simulation as decision support for the reevaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae","author":"Ambrose","year":"2004"},{"key":"10.1016\/j.clinthera.2005.07.004_bib33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.clinthera.2005.07.004_bib34","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/AAC.47.5.1672-1680.2003","article-title":"Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001","volume":"47","author":"Karlowsky","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.clinthera.2005.07.004_bib35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/320001","article-title":"Guidelines for the management of intravascular catheter-related infections","volume":"32","author":"Mermel","year":"2001","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib36","series-title":"Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Efflux pumps in Pseudomonas aeruginosa do not translate to in vivo failure in efficacy or emergence of resistance to meropenem, imipenem, or cefepime","author":"Ong","year":"2004"},{"key":"10.1016\/j.clinthera.2005.07.004_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.diagmicrobio.2005.02.010","article-title":"Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa","volume":"52","author":"Tam","year":"2005","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.clinthera.2005.07.004_bib38","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1592\/phco.2005.25.7.935","article-title":"Evaluation of pharmacodynamic target attainment between healthy subject and patient data using Monte Carlo simulation","volume":"25","author":"Kuti","year":"2005","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2005.07.004_bib39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1523-1755.2004.00412.x","article-title":"Estimating the prevalence of renal insufficiency in seniors requiring long-term care","volume":"65","author":"Garg","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinthera.2005.07.004_bib40","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ndt\/gfh707","article-title":"Assessment of renalfunction in recently admitted critically ill patients with normal serum creatinine","volume":"20","author":"Hoste","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.clinthera.2005.07.004_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2003.12.019","article-title":"Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)","volume":"24","author":"Streit","year":"2004","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.clinthera.2005.07.004_bib42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1179\/joc.2004.16.5.437","article-title":"Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: Data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States","volume":"16","author":"Friedland","year":"2004","journal-title":"J Chemother."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T12:36:04Z","timestamp":1553085364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180500127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S014929180500127X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.07.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}